Relay Therapeutics' zovegalisib granted Breakthrough Therapy designation by FDA.

Relay Therapeutics has announced that zovegalisib, a cancer treatment, has been granted Breakthrough Therapy designation by the US FDA for PIK3CA-mutant, HR+/HER2- advanced breast cancer. The designation is supported by clinical data from the ReDiscover trial, and initial Phase 1/2 data will be presented at ESMO Targeted Anticancer Therapies Congress on March 16.